HR-6166-119
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsored by Frank Pallone (D-NJ)
What it does
This bill would lower the cost of prescription drugs for American families, likely through mechanisms such as price negotiation, caps on out-of-pocket costs, or limits on drug price increases. Because only the bill's title was provided and the full legislative text was not included, the specific mechanical provisions — such as which drugs are covered, which payers are affected, and how prices would be set or enforced — cannot be determined from the available text.
Who benefits
Patients who pay high out-of-pocket costs for prescription drugs, particularly those with chronic conditions requiring ongoing medication. Medicare and Medicaid enrollees if the bill extends or expands existing drug pricing programs. Lower-income households that spend a disproportionate share of income on medications. Insurers and employers if drug costs shift to manufacturers. Generic drug manufacturers if brand-name pricing is constrained.
Who is hurt
Brand-name pharmaceutical manufacturers, who may face reduced revenue from lower negotiated or capped prices. Shareholders and pension funds with holdings in pharmaceutical companies. Biomedical researchers and startups that depend on projected drug revenues to fund development of new treatments. Pharmacy benefit managers (PBMs) whose business models depend on current pricing structures. Patients who rely on drugs that may be deprioritized for development if manufacturer incentives are reduced.
Supporters argue
Supporters argue that U.S. prescription drug prices are significantly higher than in peer nations — often two to three times the cost — and that millions of Americans ration or skip medications due to cost, with measurable consequences for health outcomes. They contend that allowing direct price negotiation or imposing cost caps corrects a market imbalance where manufacturers face no competitive pricing pressure for patent-protected drugs, and that the Inflation Reduction Act's Medicare drug negotiation program demonstrated this approach is administratively feasible.
Opponents argue
Opponents argue that constraining drug prices reduces the financial returns that fund pharmaceutical research and development, potentially slowing the pipeline of new treatments and cures. They contend that the U.S. pricing system, while costly to consumers, cross-subsidizes global innovation — and that price controls could reduce the number of new drugs brought to market, citing studies projecting meaningful declines in R&D investment under aggressive pricing limits. They further argue that the bill's full fiscal and market effects cannot be assessed without complete legislative text.
Constitutional context
Congress has broad authority to regulate drug pricing through the Commerce Clause (Art. I, §8, cl. 3) and the Taxing and Spending Clause (Art. I, §8, cl. 1), as affirmed in NFIB v. Sebelius (2012). If the bill delegates significant pricing authority to a federal agency, post-Loper Bright (2024) courts would independently review whether the statutory language clearly authorizes that delegation, without deferring to the agency's interpretation.
Checks and balances
Congress would set the drug pricing framework; executive branch agencies (likely HHS or CMS) would implement and enforce it; courts would review agency actions under the heightened post-Loper Bright standard, with no automatic deference to agency interpretations of ambiguous statutory terms.
Historical precedent
The Inflation Reduction Act of 2022 authorized Medicare to negotiate prices for a limited set of high-cost drugs, representing the first federal drug price negotiation program; pharmaceutical manufacturers challenged it in court with mixed early results.